Roche Snaps Up Memory, Gains CNS Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss drugmaker gains partnered compounds in Alzheimer’s and schizophrenia via $50 million deal.
You may also be interested in...
Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors
Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.
Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors
Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.
Tarnished HALO For Targacept/AstraZeneca Schizophrenia Drug
Partners halt development of AZD3480 in schizophrenia after Phase II failure, but will wait for ADHD trial before deciding the fate of the compound.